Clinical Research Supporting the Efficacy of hetIL-15

Admune Therapeutics LLC has selected cancer immunotherapy as the first clinical indication for our heterodimeric IL-15:IL-15Ra (hetIL-15) development program. A Phase I clinical trial has begun using our proprietary hetIL-15 through the National Cancer Institute at the National Institutes of Health. The results of those studies and additional research into the efficacy of heterodimeric IL-15 will be made available here.